Search 

Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Bionow supports business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England. Our membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms. Our membership base includes startups and early stage firms as well as established growth-oriented companies. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.

Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.

Exhibiting at booth 50 with the UK delegation, Catalyst is a clinical research organisation (CRO)that provides highly customisable solutions to the global biopharmaceutical industry through two established, branded solutions: CatalystOncology and Catalyst Flex. The company provides multi-therapeutic global resourcing and functional services through Catalyst Flex, and full-service oncology CRO offerings through Catalyst Oncology.

With over 800 staff andoffices in the United States and Europe, Catalyst's flexible service model isbuilt from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies.

Clinical Accelerator is an independent European clinical trial management organisation offering a range of clinical research and patient enrolment support services to worldwide clients in the pharmaceutical, biotechnology and medical device industries.

We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines.

Placing clinical trials in our Eastern European countries of operation allows Clinical Accelerator to achieve significant cost savings for our clients. Fast and large-scale patient recruitment is another important advantage. To ensure excellent quality of our Eastern European trials, we carefully select sites and investigators able to work to the highest quality standards with full ICH GCP compliance.

Clinical Accelerator provides client-tailored services. We are always prepared to adjust our system and procedures to the requirements of virtual, small and medium-sized biotech sponsors or larger pharma companies. We take a proactive role in the management of our projects based on intensive communication with our sponsors and joint commitment to success and always take responsibility for delivering clinical trials to agreed timeframes and within agreed budgets.

We deliver affordable clinical trials solutions with quality and speed!